Close sidebar

UK approves Australia-purchased vaccine

written by Adam Thorn | December 2, 2020

The UK has become the first major Western country in the world to approve a COVID vaccine, in a huge breakthrough moment in the battle to end the pandemic.

British Health Secretary Matt Hancock said the Pfizer/BioNTech jab – purchased by Australia – would begin being rolled out by “early next week”.

Last month, its manufacturer’s chief executive Dr Albert Bourla revealed the vaccine was “90 per cent effective” and would “help bring an end to this global health crisis”.

Advertisement
Advertisement

A spokesman from the UK’s Department of Health and Social Care said, “The government has today accepted the recommendation from the MHRA to approve Pfizer/BioNTech’s COVID-19 vaccine for use.

“This follows months of rigorous clinical trials and a thorough analysis of the data by experts at the MHRA who have concluded that the vaccine has met its strict standards of safety, quality and effectiveness.

“The joint committee on vaccination and immunisation will shortly also publish its latest advice for the priority groups to receive the vaccine, including care home residents, health and care staff, the elderly and the clinically extremely vulnerable. The vaccine will be made available across the UK from next week.”

PROMOTED CONTENT

The rollout of the vaccine will be challenging as, unlike some of its competitors, it needs to be kept at minus 70 degrees.

It’s reported that a network of 50 British hospitals are ready to deliver the first jabs with specialist vaccination centres also being built.

“The goal will be to vaccinate through the NHS right across the UK as rapidly as the company can manufacture,” said Secretary Hancock. “It will help save lives. Once we’ve protected the most vulnerable it will help us all get back to normal and back to some of the things that we love.”

“So many families have suffered, including my own. I’m just so, so pleased … 2020 has been just awful and 2021 is going to be better. Help is on its way. Help is on its way with this vaccine – and we can now say that with certainty rather than with all the caveats that normally have to put around that.

“I’m confident now, with the news today, that from spring – from Easter onwards – things are going to be better. We’re going to have a summer next year that everybody can enjoy. Between now and then we’ve got to hold our resolve.”

Last month, Australia announced it had purchased 10 million doses of the vaccine produced by Pfizer/BioNTech, which is one of the world’s leading candidates. The country has also agreed to deals with candidates from Novavax, the University of Oxford and the University of Queensland.

Manufacturing of the Pfizer vaccine is already underway and the business said it could supply up to 50 million doses in 2020 and up to 1.3 billion in 2021.

The vaccine works by injecting people with the genetic material needed to grow the “spike protein” of SAR-CoV-2 inside their owns cells, which elicits an immune response.

Phase 3 trials – the final, mass testing vaccines must go through – began on 27 July and has so far enrolled more than 43,000 participants, most of whom took the required two doses. The trial contained a mix of people from a variety of racial and ethnically diverse backgrounds.

John Bell, Regius professor of medicine at Oxford University, which is creating a rival vaccine, said Pfizer’s effort had shown “an amazing level of efficacy”.

“Today is a great day for science and humanity,” said Dr Bourla. “The first set of results from our phase three COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19.

“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen.

“With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”

BioNTech was founded by two married German scientists, Uğur Şahin and Özlem Türeci. It originally set out to develop new types of immunotherapy for cancer but has recently concentrated on tackling COVID-19.

COVID has been the biggest crisis Australian aviation has seen. In June, the wider Qantas group said it would cut 6,000 jobs altogether, or nearly 20 per cent of its workforce, and later revealed a further 2,500 ground handling jobs would be lost.

The drastic cuts followed the business’ full-year financial results showing a loss before tax of $2.7 billion and an underlying profit before tax of just $124 million.

Virgin, meanwhile, went into administration before cutting 3,000 jobs and axing the Tigerair brand.

The director-general of the International Air Transport Association has said aviation’s recovery has “hit a wall” after new figures revealed passenger traffic has flatlined.

“A resurgence in COVID-19 outbreaks – particularly in Europe and the US – combined with governments’ reliance on the blunt instrument of quarantine in the absence of globally aligned testing regimes, has halted momentum toward re-opening borders to travel,” said Alexandre de Juniac, IATA’s director general and CEO.

Total demand in September was still down 73 per cent from the same month last year, a minuscule improvement from being down 75 per cent from August.

Fly into Spring with Australian Aviation’s latest print edition. Starting from $49.95 a year, you can read comprehensive coverage on all sectors of the industry to keep you in the loop. Get your hands on the subscription today. Subscribe now at australianaviation.com.au.

Leave a Comment

Your email address will not be published. Required fields are marked *

Each day, our subscribers are more informed with the right information.

SIGN UP to the Australian Aviation magazine for high-quality news and features for just $99.95 per year